Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8).

Soria, Jean-CharlesFelip, EnriquetaCobo, ManuelLu, ShunSyrigos, Konstantinos N.Lee, Ki HyeongGoker, ErdemGeorgoulias, VassilisLi, WeiIsla, DoloresGuclu, Salih ZekiMorabito, AlessandroMin, Young JooArdizzoni, AndreaGadgeel, Shirish M.Wang, BushiChand, Vikram K.Goss, Glenwood D.2019-10-272019-10-2720150732-183X1527-7755https://hdl.handle.net/11454/42236Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer -- MAY 29-JUN 02, 2015 -- Chicago, ILeninfo:eu-repo/semantics/closedAccessAfatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8).Conference Object3315WOS:000358036901715Q1